SHARE

Axxess Pharma Inc (OTCMKTS:AXXE) provided a shareholder update for 1Q2015. In the first quarter, the company continued with its efforts of global expansion of TapouT product line. It fulfilled re-orders received from the United States military. In the first quarter, the focus was on generating additional sales via strong marketing, extending global distribution channels, introducing new, all-natural products and entering into marketing deals with globally branded large companies. The company also filed its financials for fiscal ending 2014.

The accomplishments

Axxess Pharma entered into a major promotional agreement with ROC Nation. Under the deal AllStar Health Brands associated with Roc Nation Sports on their three boxing events conducted under the throne boxing banner. The first boxing event was held at Madison Square Garden on January 9. The company together with Roc Nation Sports will promote its product line and the remaining events.

The products

Axxess Pharma Inc (OTCMKTS:AXXE) received FDA approval from the U.S. to sell its new TapouT product line including Omega-3 fish oil and other supplements in overseas markets where additional regulatory approvals are mandatory. The management is setting the platform to introduce their new round of all-natural products in 3Q2015. The latest range of products includes Protein Bars and Ready to Drink Protein Shakes. Axxess expects these products to become the biggest selling products next year. The latest range of products contains high-protein content, are flavor-tested, gluten free and lactose free. They have not more than one gram of sugar.

The management view

The management of Axxess stated that they are excited to have consummated the important boxing events, and will combine the TapouT product line into global platforms and aggressively commercialize these with new associates. In the last trading session, the stock price of Axxess dropped 0.33% to close the day at $0.0917 on share volume of 913,085 lower than average volume of 1.37 million.

LEAVE A REPLY